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Information on patterns of concomitant dietary supplement (DS) and prescription
medication (PM) use among US adults is limited. Thus, the prevalence of concomitant
DS and PM use as a function of doctor-informed medical conditions (DIMC) was
determined in a cross-sectional, observational study of a nationally representative
sample of noninstitutionalized, civilian adults aged 20 years in the United States
(N¼9,950) from the 2005-2008 National Health and Nutrition Examination Survey
(NHANES). Data were weighted for the complex, multistage, probability sampling
design. Approximately one third (34.3%) of all US adults reported concomitant DS and
PM use (approximately one in three adults). The prevalence of use was signiﬁcantly
higher among those with vs without a DIMC (47.3% vs 17.3%). Adults with a DIMC were
more than two and a half times more likely to concomitantly use DS and PM than adults
without a DIMC, after adjustment for sex, age, education, and household income.
Multivitamin plus other ingredient(s), followed by antacids and multivitamin plus
botanical ingredient(s), were the most prevalent DS categories used with a PM among
those with and without a DIMC. The most prevalent PM categories used with a DS were
cardiovascular agents (among those with a DIMC) and hormones (among those without
a DIMC). These ﬁndings demonstrate that presence of a DIMC may be a risk factor for
concomitant DS and PM use among US adults. Multivitamins containing nonvitamin or
mineral ingredients are more commonly used than standard multivitamins with PM by
US adults. This may be an emerging trend that warrants further consideration.
J Acad Nutr Diet. 2014;114:1784-1790.M
ORE THAN HALF OF US ADULTS REPORT USING
at least one dietary supplement (DS) during the
previous 30 days.1,2 Patients have reported using
DS and medications with potential DSedrug in-
teractions in various clinical settings.3-6 Herbal DS may alter
drug pharmacokinetics by inducing or inhibiting cytochrome
P450 drug metabolizing enzymes and activity,7,8 thereby
altering the effectiveness of prescription medications (PM).
A review of documented interactions between DS and PM
found that DS containing St John’s wort, magnesium, calcium,
iron, and Gingko biloba had the highest number of potentialinteractions, whereas DS containing ﬂaxseed, Echinacea, and
yohimbe had the highest number of contraindications.9 Prior
investigations have estimated the prevalence of concomitant
DS and PM use as a percentage of PM users.10-12 However, in-
formation to aid health care and dietetics practitioners in
identifying populations at risk for experiencing DS and PM
interactions remains limited.
In our study, the prevalence proportion (percent) and point
prevalence (total number) of concomitant DS and PM use
among all US adults, according to doctor-informed medical
conditions (DIMC) were determined by analyzing data from
the 2005-2008 National Health and Nutrition Examination
Survey (NHANES), a nationally representative sample of
noninstitutionalized civilian adults and children in the United
States. Our analysis included use of the NHANES Dietary
Supplement Database (NHANES-DSD), which is the largest
publicly available national database of DS use. The DS cate-
gories most commonly used with a PM, as well as the PM
categories most commonly used with DS, are also reported.ª 2014 by the Academy of Nutrition and Dietetics. This is an open access




Data were drawn from NHANES, which is administered and
managed by the National Center for Health Statistics
(NCHS). Comprehensive sample selection and data collection
methods are detailed elsewhere.13 Brieﬂy, sampling is per-
formed with a complex, multistage, probability sampling
design to obtain a nationally representative sample of
noninstitutionalized civilian adults and children in the
United States. This study used data pooled from the 2005-
2006 (N¼10,348) and 2007-2008 (N¼10,149) data collection
series. Of the 19,712 subjects with data from both the
household interview and mobile examination center, 10,480
subjects aged 20 years were eligible for inclusion. Subjects
who were pregnant (n¼382), and those with missing data
for DS use (n¼8), PM use (n¼5), education (n¼8), marital
status (n¼4), or DIMC (n¼123) were excluded. The ﬁnal
sample size was composed of 5,016 men and 4,934 women.
NHANES 2005-2006 and 2007-2008 surveys were approved
by the NCHS Research Ethics Review Board.
DS Use and Classiﬁcation
DS use in the past month was assessed by trained in-
terviewers using the computer-assisted personal inter-
viewing (CAPI) system during the household interview. A
full description of the DS data collection and CAPI system
is provided elsewhere.14,15 Antacids and calcium and/or
magnesium-containing antacids taken as a DS were included
in DS use variables. To minimize subjective classiﬁcation, DS
were classiﬁed into 18 mutually exclusive subgroups by a
systematic iterative sorting procedure that used the ingre-
dient count variables (vitamin, mineral, amino acid, botan-
ical, and other) and search terms in the DS name variable and
ingredient name variable associated with each DS in the
NHANES-DSD. A total of 3,106 distinct DS ID numbers derived
from the sample were grouped into relevant categories.
Multivitamin categories were deﬁned to be consistent with
previous NHANES publications,1,16 such that multivitamins
were identiﬁed as containing 3 vitamins, and may or may
not contain minerals. However, standard multivitamins,
which were deﬁned as containing no nonvitamin or mineral
ingredients, were differentiated from multivitamins con-
taining botanicals and multivitamins containing other non-
botanical ingredients. The detailed classiﬁcation schematic is
provided in Figure 1 (available online at www.andjrnl.org).
PM Use
PM use during the past month was assessed using the CAPI
system during the household interview. PM was matched to
the PM database Lexicon Plus, a proprietary database of
Cerner Multum, Inc, used by NCHS. A full description of the
database and PM classiﬁcation scheme is provided else-
where.17 Brieﬂy, PMs were classiﬁed according to the PM’s
ﬁrst-level drug therapeutic category of the 3-level nested
category system. Prescription antacids were included in the
PM database, not the DS database. Prescription DS, including
calcium (except calcium acetate) and ﬂuoride (except topical
gel or cream formulations), were included in the DS database.
Over-the-counter niacin, niacinamide, and nicotinic acid
were included in the DS database, whereas prescriptionNovember 2014 Volume 114 Number 11 JOniacin, potassium, and sodium were included in the PM
database.
DIMC and Covariates
Presence of any DIMC and covariates were also assessed using
the CAPI system during the household interview. DIMC
included asthma, arthritis, congestive heart failure, coronary
heart disease, angina, angina pectoris, heart attack, stroke,
high blood pressure, high cholesterol, emphysema, chronic
bronchitis, any liver condition, thyroid problem, cancer or
malignancy, weak/failing kidneys, dialysis during past 12
months, or osteoporosis/brittle bones. Similar conditions
were grouped to obtain DIMC categories. Covariates were
categorized as follows: sex (male/female), age (20 to 39 years,
40 to 59 years, or 60 years), marital status (married or living
with a partner or single), education (less than high school
graduate or high school graduate or some college or college
graduate), and family income (unsure, <$20,000, $20,000 to
$44,999, $45,000 to $74,999, or $75,000).
Statistical Analysis
SAS statistical analysis software (version 9.1.2, 2004, SAS
Institute Inc) was used to perform analyses. All analyses were
adjusted for the complex sampling design of NHANES by
specifying the stratum and cluster variable, in addition to the
4-year mobile examination center weight, to ensure sampling
errors were estimated by the Taylor series (linearization)
method, as suggested in the NHANES analytic guidelines.18
The ﬁnal sample subpopulation and analyses for subgroups
were speciﬁed using the domain statement, or by including
the domain variable in the surveyfreq procedure, such that
variance estimates were based on the full-sample size of
subjects with data available from the household interview
and the mobile examination center. The surveyfreq and sur-
veylogistic procedure in SAS were used to derive descriptive
and logistic regression analysis data (after adjustment for sex,
age, education, and household income). A conservative 99%
CI was calculated for each prevalence estimate and odds
ratio. Signiﬁcant differences were deﬁned as nonconvergent
CIs and odds ratios excluding 1.00 in the CI. The point prev-
alence (total of US adults) was calculated according to the
NHANES analytic guidelines for calculating population
counts.19 Brieﬂy, the total prevalence proportion (percent
of all US adults) was multiplied by the population total of US
noninstitutionalized civilian adults aged 20 years for 2005-
2008 reported by the Center for Population Statistics20; that
is, 1/2 (2005-2006 population totals)þ1/2 (2007-2008 population
totals)¼210,156,452.
RESULTS AND DISCUSSION
Several demographic characteristics were signiﬁcantly asso-
ciated with concomitant DS and PM use (Table 1). Men were
less likely than women to use DS and PM. Subjects aged 20 to
39 years and 40 to 59 years were less likely, respectively, than
those aged 60 years to use DS and PM. Subjects with edu-
cation less than that of college graduates were signiﬁcantly
less likely to use DS and PM. Similarly, subjects with a
household income <$75,000 per year were signiﬁcantly less
likely to use DS and PM. Multiple DS users and multiple PM
users were more likely than single users to concomitantly use
DS and PM. After adjustment for age, married subjects, andURNAL OF THE ACADEMY OF NUTRITION AND DIETETICS 1785
Table 1. Demographic and concomitant dietary supplement (DS) and prescription medication (PM) use characteristicsa of a
nationally representative sample of 9,950 noninstitutionalized, civilian adults aged 20 years in the United States enrolled in the
2005-2008 National Health and Nutrition Examination Survey
Characteristic % (99% CI)
DS and PM Use
% (99% CI) Odds ratio (99% CI)
Sex
Male 49.0 (47.9-50.1) 26.5 (23.9-29.1) 0.51 (0.45-0.57)
Female 51.0 (49.9-52.1) 41.8 (38.8-44.9) 1.00
Age (y)
20-39 37.0 (34.4-39.5) 17.1 (14.4-19.7) 0.13 (0.11-0.16)
40-59 39.6 (37.2-41.9) 34.6 (31.5-37.7) 0.34 (0.29-0.41)
60 23.5 (20.6-26.3) 61.1 (56.8-65.3) 1.00
Marital statusb
Married 57.1 (54.1-60.1) 36.5 (33.6-39.5) 1.03 (0.87-1.21)
Living with partner 7.54 (6.22-8.87) 20.2 (14.4-26.0) 0.77 (0.52-1.14)
Single 35.3 (32.3-38.4) 33.8 (30.4-37.2) 1.00
Education
< High school graduate 19.0 (16.2-21.9) 23.8 (20.4-27.2) 0.41 (0.33-0.51)
High school graduatec 25.3 (23.2-27.5) 31.7 (27.4-35.9) 0.61 (0.49-0.76)
Some college 30.1 (28.2-31.9) 35.8 (32.2-39.3) 0.74 (0.62-0.88)
College graduate 25.6 (21.7-29.5) 43.1 (39.1-47.1) 1.00
Household income
Unsured 2.60 (1.98-3.22) 32.3 (23.0-41.6) 0.77 (0.52-1.14)
<$20,000 14.7 (12.6-16.7) 31.2 (26.6-35.7) 0.72 (0.58-0.91)
$20,000-$44,999 29.2 (26.1-32.2) 33.3 (29.5-37.1) 0.81 (0.67-0.98)
$45,000-$74,999 22.9 (20.6-25.2) 32.9 (29.2-36.6) 0.80 (0.66-0.96)
$75,000 30.7 (26.7-34.7) 38.0 (34.7-41.4) 1.00
DS use
Multiple use (2) 27.5 (24.3-30.7) 71.6 (67.5-75.8) 1.57 (1.26-1.97)
Single use (1) 23.7 (22.3-25.2) 61.5 (57.8-65.3) 1.00
No use (0) 48.7 (45.4-52.1) — —
PM use
Multiple use (2) 40.2 (37.7-42.6) 62.6 (58.4-66.8) 1.41 (1.20-1.66)
Single use (1) 17.0 (15.7-18.3) 54.1 (48.5-59.7) 1.00
No use (0) 42.9 (40.4-45.3) — —
aEstimates include adjustment for complex sampling design; 4-year mobile examination center exam weight applied.
bAdjusted for age.
cOr equivalent.
dIncludes subject response of “don’t know/unsure” during the household interview as well as missing data.
RESEARCHsubjects living with a partner were not signiﬁcantly more or
less likely than single subjects to use DS and PM; thus,
marital status was not included as a covariate in subsequent
logistic regression models.
Prevalence estimates for DS and PM use are presented
in Table 2. Half of US adults reported DS use, and more
than half reported PM use. The prevalence of any DS, or
any PM use was signiﬁcantly higher among those with any1786 JOURNAL OF THE ACADEMY OF NUTRITION AND DIETETICSDIMC than those without any DIMC. The prevalence of DS
use was highest among those with osteoporosis, followed
by those with thyroid, cancer, arthritis, heart/vascular,
kidney, diabetes, respiratory, and liver conditions. The
prevalence of PM use was highest among those with a
kidney condition, followed by thyroid, osteoporosis, dia-
betes, cancer, arthritis, respiratory, heart/vascular, and
liver conditions.November 2014 Volume 114 Number 11
Table 2. Prevalencea of dietary supplement (DS) and prescription medication (PM) use according to doctor-informed medical
condition (DIMC) among a nationally representative sample of 9,950 noninstitutionalized, civilian adults aged 20 years in the
United States enrolled in the 2005-2008 National Health and Nutrition Examination Survey




Within All US Adults
Concomitant DS
and PM Use
DIMC % (99% CI) % (99% CI) % (99% CI) Odds ratiob (99% CI) % (99% CI) Nc
Total 51.3 (47.9-54.6) 57.1 (54.7-59.6) — — 34.3 (31.9-36.8) 72,083,663
Any DIMC 58.7 (54.7-62.6) 75.2 (72.5-78.0) 47.3 (44.0-50.6) 2.62 (2.13-3.21) 26.8 (24.4-29.3) 56,321,929
No DIMC 41.6 (37.5-45.7) 33.4 (30.5-36.4) 17.3 (14.7-19.9) — 7.50 (6.18-8.82) 15,761,734
Arthritis 61.9 (58.1-65.7) 82.7 (80.0-85.5) 53.4 (50.2-56.6) 1.79 (1.46-2.20) 13.5 (11.9-15.2) 28,371,121
Heart/vascular 59.9 (55.8-63.9) 76.8 (73.7-79.9) 49.1 (45.4-52.9) 1.86 (1.67-2.07) 16.5 (14.8-18.1) 34,675,815
Respiratory 54.1 (46.9-61.2) 78.4 (72.8-84.0) 45.8 (39.8-51.8) 1.33 (0.98-1.80) 2.90 (2.18-3.61) 6,094,537
Liver 51.1 (41.2-61.1) 70.9 (64.1-77.7) 41.3 (33.1-49.4) 1.31 (0.86-2.00) 1.41 (1.07-1.75) 2,963,206
Thyroid 67.1 (60.8-73.2) 90.8 (87.8-93.8) 62.4 (56.2-68.6) 2.06 (1.58-2.69) 6.15 (5.08-7.23) 12,924,622
Cancer 66.9 (60.3-73.5) 84.9 (80.7-89.1) 59.3 (53.2-65.5) 1.67 (1.32-2.11) 5.15 (4.31-6.00) 10,823,057
Diabetes 57.2 (52.0-62.4) 88.9 (85.4-92.3) 52.4 (46.7-58.1) 1.75 (1.42-2.15) 6.99 (6.03-7.95) 14,689,936
Kidney 58.2 (30.2-86.2) 100.0 (100-100) 58.2 (30.2-86.2) — 0.09 (0.02-0.15) 189,141
Osteoporosis 76.9 (72.0-1.9) 89.7 (85.5-93.8) 70.5 (65.0-76.1) 2.42 (1.90-3.09) 3.82 (2.93-4.71) 8,027,976
aEstimates include adjustment for complex sampling design; 4-year mobile examination center exam weight applied.
bAdjusted for sex, age, education, and household income.
cTotal US adults calculated by multiplying the total prevalence proportion (percent of all US adults) by the population total of US noninstitutionalized civilian adults aged 20 years.
RESEARCHApproximately one third of all US adults reported
concomitant DS and PM use, representing 72,083,663 adults
(approximately one in three adults). The prevalence of
concomitant DS and PM use was signiﬁcantly higher among
those with any DIMC than those without, representing
approximately one in two adults with a DIMC relative to
approximately one in six adults without DIMC. The preva-
lence of concomitant DS and PM use was highest among
those with osteoporosis, followed by thyroid, cancer, kidney,
arthritis, diabetes, heart/vascular, respiratory, and liver con-
ditions. The point prevalence (total number of US adults) of
concomitant DS and PM use was highest among those with
heart/vascular conditions, followed by arthritis, diabetes,
thyroid, cancer, osteoporosis, respiratory, liver, and kidney
conditions. In regression models, DIMC status was signiﬁ-
cantly associated with concomitant DS and PM use. Those
with any DIMC, as well as each individual DIMC (with the
exception of respiratory and liver conditions), were signiﬁ-
cantly more likely to report concomitant DS and PM use than
those without these respective conditions, after adjustment
for covariates.
Prevalence of DS categories according to DIMC status are
shown in panel A of Figure 2. Multivitamin plus other was the
most prevalent DS category used concomitantly with a PM,
among both those with and without a DIMC. When DS cat-
egories were ranked according to prevalence among those
with any DIMC, multivitamin plus other was followed by
antacid, multivitamin plus botanical, single vitamin, standard
multivitamin, ﬁsh oil and n-3 fatty acids, multicomponent
botanical, other, joint, and single mineral. The prevalence of
use for single botanical, calcium combination, digest, calciumNovember 2014 Volume 114 Number 11 JOplus vitamin D, coenzyme Q10, vitamin/mineral complex,
multibotanical, and single amino acid was <1.0% among
those with and without any DIMC.
Patterns of PM categories differed to some extent according
to DIMC status (panel B of Figure 2). Among those with a
DIMC, cardiovascular agents (16.2%) were the most prevalent
PM category used concomitantly with a DS, followed by
central nervous system agents, hormones, metabolic agents,
psychotherapeutic agents, anti-infectives, gastrointestinal
agents, respiratory agents, miscellaneous agents, coagulation
modulators, topical agents, antineoplastics, nutrition-related
products, and immunologic agents. Among those without a
DIMC, hormones (3.0%) were the most prevalent PM category
used concomitantly with a DS, followed by central nervous
system agents, cardiovascular agents, anti-infectives, psy-
chotherapeutic agents, respiratory agents, gastrointestinal
agents, topical agents, miscellaneous agents, coagulation
modulators, metabolic agents, antineoplastics, nutrition-
related products, and immunologic agents. Among both
those with and without a DIMC, biologic, plasma expanders,
and alternative medicine categories had prevalence estimates
of 0% (data not shown).
This is the largest population-based study to date of a na-
tionally representative sample of noninstitutionalized, non-
pregnant US adults that describes the prevalence and nature
of concomitant DS and PM use. The estimates obtained in
our analysis are similar to estimates reported previously
for DS use2,12 alone and PM use11 alone. Studies of nationally
representative data from more than 10 years ago reported
18%10 and 16%11 of PM users concomitantly used DS and PM.
A more recent study of older adults (aged 57 to 85 years)URNAL OF THE ACADEMY OF NUTRITION AND DIETETICS 1787
AB
Figure 2. Prevalence (% and 99% CI) of (A) dietary supplement (DS) categories used concomitantly with a prescription medication
(PM) and (B) PM categories used concomitantly with a DS, among a nationally representative sample of 9,950 noninstitutionalized,
civilian adults aged 20 years in the United States enrolled in the 2005-2008 National Health and Nutrition Examination Survey.
Stratiﬁed according to doctor-informed medical condition (DIMC) status and adjusted for complex sampling design; 4-year sample
weights applied. Black bar denotes those with any DIMC; gray bar denotes those with no DIMC. CNS¼central nervous system.
RESEARCH
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RESEARCHreported that 52% of PM users also use DS.12 Additional
analysis of the data in this study indicate that 69.3% (99% CI
65.0 to 73.6) of PM users aged 57 years concomitantly use
DS and PM, which is somewhat higher than the 52% esti-
mated by Qato and colleagues12 for older adults, suggesting
an increase in prevalence in this age group in recent years.
Both DS and PM use have been shown to increase with
age,2,12 and in addition to age, the ﬁndings that female sex,
higher education, greater income levels, and presence of a
chronic condition were associated with concomitant DS and
PM use corroborate reports of others.21
Nonvitamin/mineral DS were previously documented to be
the most common form of complementary and alternative
medicine used by US adults.22 The percent of Americans
reporting DS use has increased in recent years, from >40%
(1988-1994) to >50% (2003-2006).1 DS users report using
DS to improve or maintain overall health, as well as for
speciﬁc reasons, including primarily to promote bone health
among women and heart health among men.23 Despite
popularity of DS, concerns persist regarding purity, toxicity,
and mislabeling because regulation of DS under the 1994
Dietary Supplement Health and Education Act is limited
relative to that of PM. Several surveys suggest the percent of
patients who do not disclose their complementary and
alternative medicine use to health care professionals may
be >60%.24-26 Thus, the risk for potential interactions be-
tween DS and PM to go undetected remains substantial.
Information on the types of DS used by individuals with
chronic disease may assist health care professionals in
determining whether a patient may be at risk for a DS and
PM interaction.
The patterns of DS categories used with a PM were similar
among those with and without a DIMC. Similar to our ﬁnd-
ings, multivitamins have been identiﬁed as the most common
DS used by US adults by other investigators.1,2,12,16 However,
this analysis documents for the ﬁrst time that multivitamins
containing other or botanical ingredients were more
commonly consumed with a PM than standard multivitamins
containing only vitamin or mineral ingredients. Multivitamin
plus botanical DS were the third most common DS used with
a PM—more common than both single botanical DS and
multibotanical DS. This is concerning because botanical in-
gredients, including herbal DS, are known to induce or inhibit
cytochrome P450 drug metabolizing enzymes and activity7,8
and interfere with PM metabolism.27,28 One of the most
common botanical ingredients in this category of DS was
Ginkgo biloba, which may interact with several PMs9,29 and
may cause cancer in animals.30 The term multi, multivitamin,
or vitamin was present in 70% of label names in the multi-
vitamin plus other category and in 51% of label names in the
multivitamin plus botanical category (data not shown), sug-
gesting a consumer preference for multivitamins that
advertise or include these additional nonvitamin or mineral
ingredients.
In contrast to the DS categories, the PM categories used
with DS differed somewhat between those with and without
a DIMC. The ﬁnding that cardiovascular agents were the
most common PM used with DS among those with a DIMC
was also observed by Qato and colleagues12 among older
adults in the United States. Cardiovascular agents, including
antihypertensive and antiarrhythmic agents, appear to be
among the most common drug classes to have suspectedNovember 2014 Volume 114 Number 11 JOinteractions with DS in clinical trials and case reports.29 This
is likely due to the high prevalence of heart and vascular
conditions in the US population.
This study has some limitations. DIMC status was deter-
mined by self-report; thus, some participants may have
incorrectly or inadequately reported their conditions. Popu-
lation estimates of potential DS and PM interactions ﬁrmly
established in the literature were not ascertained; thus,
we cannot conclusively determine the number at risk for
known interactions. Nonetheless, using a large DS database
with ingredient information permitted identiﬁcation of
nonvitamin or mineral ingredients, including botanicals,
contained within multivitamins.CONCLUSIONS
Our analysis identiﬁed the presence of a DIMC as a risk factor
for concomitant DS and PM use among US adults. Individuals
with a DIMC had a higher prevalence of DS use (58.7% vs
41.6%) and PM use (75.2% vs 33.4%), than those without a
DIMC. Thus, the increased prevalence of concomitant DS and
PM among those with a DIMC is likely due to increased use of
DS, in addition to PM, rather than increased use of PM alone.
Among those with a DIMC, the prevalence of DS use was
>50% for all types of DIMC. Thus, it may not be feasible to
identify individuals with a speciﬁc condition that merit
increased attention relative to others. Rather, these data
suggest that a broad spectrum of patients with varied DIMCs
may beneﬁt from education and guidance on the risk of DS
and PM interactions, particularly the potential of DS to
interfere with PM metabolism and increase or inhibit PM
potency. In addition to providing patients with education on
the limitations of current regulatory practices to ensure
safety, reliable sources of DS information, and reading label
information, dietetics practitioners may consider encour-
aging patients to discuss and disclose their supplement use
with their physician and team of health care providers.
In addition, the observation that multivitamins containing
other or botanical ingredients were more commonly
consumed than standard multivitamins warrants further
clinical attention. The increasing complexity of combinations
of ingredients contained in DS may also require explicit
evaluation by health care and dietetics practitioners. In-
quiries about patient DS use in an attempt to screen for po-
tential DS and PM interactions may beneﬁt from identifying
ingredient information directly from labels. Multivitamin DS,
in particular, may need more scrupulous evaluation and
should not be assumed to contain only safe ingredients.References
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Category DSD ID counta
Standard multivitamin: 3 vitamins and may include minerals; no amino acid, botanical, or
other ingredients
155
Vitamin and/or mineral complex: 2 vitamins, 2 minerals, or 1 vitamin and 1 mineral; no
amino acid, botanical, or other ingredients
126
Antacid: identiﬁed by search terms antacid or calcium and magnesium / 32
Calciumþvitamin D: identiﬁed by search terms calcium and vitamin D 35
Calcium combination: identiﬁed by search terms calcium, cal, or osteo; excludes
calcium plus vitamin D and antacids
3
Fish oil and n-3 fatty acid: identiﬁed by search terms ﬁsh, omega-3, DHA, EPA,
salmon, cod, and ﬂax
7
Vitamin and/or mineral complex: remaining vitamin and/or mineral complex DS; excludes
calcium plus vitamin D, antacid, calcium combination, and ﬁsh oil and n-3
49
Multimineral: 3 minerals; no vitamin, amino acid, botanical, or other ingredients 14
Calcium combination: identiﬁed by search term calcium, cal, or osteo / 14
Single vitamin: 1 vitamin; no mineral, amino acid, botanical, or other ingredients 109
Single mineral: 1 mineral; no vitamin, amino acid, botanical, or other ingredients 95
Multicomponent botanical: 1 botanical AND 1 vitamin OR 1 mineral OR 1 amino
acid OR 1 other ingredient
917
Multivitamin plus botanical: 3 vitamins and 1 botanical, may include minerals
and amino acids
/ 402
Multicomponent botanical: remaining multicomponent botanical DS; excludes
multivitamin plus botanical
515
Multibotanical: >1 botanical; no vitamin, mineral, amino acid, or other ingredients 105
Single botanical: 1 botanical; no vitamin, mineral, amino acid, or other ingredients 250
Single amino acid: 1 amino acid; no vitamin, mineral, botanical, or other ingredients 52
Other: 1 other ingredient; no botanicals 1,283
Multivitamin plus other: 3 vitamins and 1 other ingredient, may include minerals
and amino acids, but not botanicals
/ 373
Antacid: identiﬁed by search term antacid 55
Calcium combination: identiﬁed by search terms calcium, cal, or osteo 55
Fish oil and n-3 fatty acids: identiﬁed by search terms ﬁsh, omega-3, DHA, EPA,
salmon, cod, or ﬂax
157
Joint: identiﬁed by search term glucosamine, MSM, hyaluronic acid, cosamin, or chondroitin 158
Digestive: identiﬁed by search terms ﬁber, probiotics, acidophilus, dophilus, lactobacillus,
lactase, amylase, protease, lipase, trypsin, chymotrypsin, pancreatin, or bromelain
84
(continued on next page)
Figure 1. Classiﬁcation scheme of dietary supplement (DS) using ingredient count variables in the National Health and Nutrition
Examination Survey-Dietary Supplement Database (DSD) 2005-2008. Ingredient count variable names in National Health and
Nutrition Examination Survey-Dietary Supplement Database¼vitamin count, “dsdcntv”; mineral count, “dsdcntm”; amino acid
count, “dsdcnta”; botanical count, “dsdcntb”; and other count, “dsdcnto.”
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Category DSD ID counta
Coenzyme Q-10: identiﬁed by search term Q-10, Q10, or Q 10 51
Other: remaining miscellaneous DS, such as DS containing electrolytes, melatonin, lipoic acid,
yeast, prohormones, protein, creatine, and cider vinegar
268
Other, no information: remaining DS with product information not available 82
aThe count of distinct ID numbers in the “dsdsupid” variable assigned to DS recorded in the National Health and Nutrition
Examination Survey-Dietary Supplement Database. Total distinct DS ID numbers in the sample classiﬁed into mutually exclusive
groups¼3,106.
Figure 1. (continued) Classiﬁcation scheme of dietary supplement (DS) using ingredient count variables in the National Health and
Nutrition Examination Survey-Dietary Supplement Database (DSD) 2005-2008. Ingredient count variable names in National Health
and Nutrition Examination Survey-Dietary Supplement Database¼vitamin count, “dsdcntv”; mineral count, “dsdcntm”; amino acid
count, “dsdcnta”; botanical count, “dsdcntb”; and other count, “dsdcnto.”
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